A joint venture by Sony and Olympus, which makes medical equipment, will now proceed after the deal was delayed pending approval from China’s competition authority. The companies announced that they have now received all necessarily approval. Sony is investing $535 million into Olympus in efforts to increase its competitive stance within the medical equipment market. Olympus dominates about 70 percent of the sector, according to reports, despite being more well-known for its camera products. Additionally, while the two companies did not say which specific competition regulator was delaying the deal, sources confirmed to the media that it was China’s authority. The parties had originally planned to launch the venture on April 1.
Featured News
Homebuyers’ Antitrust Case Against Top Brokerages Survives Key Court Challenge
Mar 30, 2026 by
CPI
KFTC Probes Paint Industry Over Suspected Price-Fixing Amid Cost Surge
Mar 30, 2026 by
CPI
Sysco to Acquire Jetro Restaurant Depot in $29 Billion Deal
Mar 30, 2026 by
CPI
Australia’s ACCC Faces Pressure to Approve Fuel Collaboration Among Miners
Mar 30, 2026 by
CPI
UK Regulator Launches Probe Into Major Firms Over Suspected Fake Reviews
Mar 30, 2026 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Competitor Collaborations
Mar 26, 2026 by
CPI
Between Scylla and Charybdis – Navigating Transatlantic Antitrust Currents
Mar 26, 2026 by
Tilman Kuhn & Niklas Brüggemann
Cartel Enforcement Moves Into the Labor Market: Trends and Implications
Mar 26, 2026 by
Andreas Kafetzopoulos & Caroline Janssens
Rethinking Buy-Side Antitrust “Group Boycotts”
Mar 26, 2026 by
Craig Falls & Brendan McGuire
Positive Collaborations: The Tools Available to Competition Authorities to Encourage Beneficial Interactions Between Competitors
Mar 26, 2026 by
Rona Bar-Isaac & Thomas Withers